digital health startups weight loss glp-1 Dr. Craig Primack talks Hims & Hers launching its own offering as demand rises An Instagram ad for NextMed

Provides Weight and Metabolic Control: Obesity, insulin resistance, and hyperglycemia are established risk factors for dementia

A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease

Precision analytics

Customers will be educated on this expanding assortment of FDA-approved medications, and if determined clinically appropriate by their providers, will be given the opportunity to transition seamlessly to those medications

After full-text assessment, we excluded studies on diabetes mellitus ( n = 154), studies on Parkinson or neurodegenerative conditions ( n = 8), and in vitro, animal and human studies that did not investigate pain as primary and/or secondary outcome ( n = 130)

How to choose your GLP-1 provider Five questions, in order